White W G, Freestone D S, Bowker C H, Barnes G M, Letley E, Ferris R D
Dev Biol Stand. 1976;33:202-6.
A single intranasal dose of 10(7.0)EID50 recombinant WRL 105 strain live attenuated influenza vaccine was administered intranasally to 193 volunteers either as nose drops or by one of three spray devices which produced sprays of differing physical characteristics. In volunteers with homologous hemagglutinating inhibiting antibody titres of less than or equal to 20 before vaccination, seroconversion rates varied widely from 80% following the administration of drops to 71%, 57% and 28% with each of the spray devices. In the week following vaccination 16 (22%) of 74 volunteers who were found to show a fourfold or greater antibody response took analgesics to control symptoms in comparison with 4 (7%) of 58 volunteers who exhibited no serological response to vaccination (p less than 0.05). However, neither of the occurrence of upper respiratory nor systemic symptoms were significantly different in these two groups and the level of attenuation of the recombinant WRL 105 strain appears to be acceptable for future use.
将10(7.0)EID50重组WRL 105株减毒活流感疫苗的单剂量经鼻给予193名志愿者，给药方式为滴鼻或使用三种产生不同物理特性喷雾的喷雾装置之一。在接种疫苗前同源血凝抑制抗体滴度小于或等于20的志愿者中，血清转化率差异很大，从滴鼻给药后的80%到每种喷雾装置给药后的71%、57%和28%。在接种疫苗后的一周内，74名被发现有四倍或更高抗体反应的志愿者中有16名(22%)服用镇痛药来控制症状，而58名对疫苗无血清学反应的志愿者中有4名(7%)(p<0.05)。然而，这两组在上呼吸道症状或全身症状的发生方面均无显著差异，重组WRL 105株的减毒水平似乎可用于未来使用。
